---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023518"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:53:02.934818+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q3 net loss $24.7M; cash $114.4M; atacicept Ph2b ORIGIN data early Q1 2023

## Summary
- Net loss of $24.7M ($0.91 per share) vs $7.6M loss YoY; cash burn $46.4M YTD.
- Cash, equivalents, and marketable securities $114.4M; additional $20M drawn from credit facility in Nov 2022; funds operations to Q2 2024.
- Phase 2b ORIGIN trial of atacicept in IgA nephropathy topline data expected early Q1 2023.
- Initiated pivotal Phase 3 COMPASS trial of atacicept in lupus nephritis.
- Positive Phase 2 MAU868 results in BK viremia presented; plan to start Ph2b/Ph3 trial in 2023.

## SEC filing metadata
- accession: 0000950170-22-023518
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017022023518/0000950170-22-023518-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017022023518/vera-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023518
- JSON: https://secwatch.observer/filing/0000950170-22-023518.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023518.txt

## Key facts
- Earnings Releases
  Vera Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income a net loss of $24.7 million, or a net loss per diluted share of $0.91, EPS $0.91.
  - Period: the quarter ended September 30, 2022
  - Net income: a net loss of $24.7 million, or a net loss per diluted share of $0.91
  - EPS: $0.91
  - Result: reported results
  source text: For the three months ended September 30, 2022, the company reported a net loss of $24.7 million, or a net loss per diluted share of $0.91, compared to a net loss of $7.6 million, or a net loss per diluted share of $0.36, for the same period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000095017022023518/0000950170-22-023518-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.